Trillium Therapeutics Inc. operates as a biopharmaceutical research and development company. It focuses on the immune system and its regulation. The company specializes in the discovery and development of protein therapeutics, such as monoclonal antibodies, secreted proteins, and peptides. It involves in therapeutic areas, including autoimmune disease, cancer, necrotizing enterocolitis, and transplantation. Trillium Therapeutics Inc. was formerly known as Transplantation Technologies Inc. and changed its name in May 2003. The company was founded in 1996 and is based in Toronto, Canada.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Trillium Therapeutics Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Trillium Therapeutics Inc market cap is $1.64B.
What is the 52-week high for Trillium Therapeutics Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Trillium Therapeutics Inc 52 week high is $20.96 as of September 09, 2025.
What is the 52-week low for Trillium Therapeutics Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Trillium Therapeutics Inc 52 week low is $5.80 as of September 09, 2025.
What is Trillium Therapeutics Inc stock price today?
Trillium Therapeutics Inc stock price today is $18.45.
What was Trillium Therapeutics Inc stock price yesterday?
Trillium Therapeutics Inc stock price yesterday was $17.97.
What is the PE ratio of Trillium Therapeutics Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Trillium Therapeutics Inc’s P/E ratio is 74.87.
What is the Price-to-Book ratio of Trillium Therapeutics Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Trillium Therapeutics Inc P/B ratio is 7.9220.
What is the 50-day moving average of Trillium Therapeutics Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Trillium Therapeutics Inc 50-day moving average is $17.71.